May 24, 2022

Volume XII, Number 144


Lee Mia Nagao Ph.D.

Lee Mia Nagao partners with pharmaceutical innovators to identify and overcome regulatory and product-development obstacles as they shepherd their products from the lab to the marketplace. Driven by her own background as a scientist, Lee is passionate about helping clients maximize efficiency in the product development lifecycle so that high-quality, life-saving products reach patients quickly and clients have more time to focus on new innovations.

Advising Pharmaceutical and Biopharmaceutical Companies

Lee advises domestic and international clients on current and emerging regulatory oversight of biologics and pharmaceutical drug development and manufacturing, including drug-device combination products. She works with clients to address complex issues related to pharmaceutical packaging, drug-device combination products, supply chains, nonclinical toxicology and clinical pharmacology. Lee is skilled in providing strategic counsel on aspects of chemistry, manufacturing and controls (CMC), risk assessment and management strategies, lifecycle management, current good manufacturing practices (CGMPs), and regulatory frameworks for drug master files and other regulatory submissions.

Clients value Lee’s guidance on detailed regulatory requirements for pharmaceuticals as well as on the creation of industry collaborations, including public-private partnerships. She represents industry groups before regulatory agencies and industry and scientific organizations throughout the world, including:

  • U.S. Food & Drug Administration
  • Health Canada
  • European Medicines Association
  • United Kingdom Medicines and Healthcare Products Regulatory Agency
  • China National Medical Products Administration
  • Brazilian Health Regulatory Agency (ANVISA)
  • Japan Pharmaceuticals and Medical Devices Agency
  • United States Pharmacopeia

Articles in the National Law Review database by Lee Mia Nagao Ph.D.